The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KROS | -69.39% | -77.07% | -25.5% | -15% |
| S&P | +13% | +86.41% | +13.26% | +146% |
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.
The company appointed a new director and an analyst reiterated his position on the stock.
A sympathetic reaction to a competitor's drug helped push the clinical-stage pharmaceutical company's shares higher.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $14.26M | 3575.8% |
| Gross Profit | $13.87M | 18639.2% |
| Gross Margin | 97.23% | 78.2% |
| Market Cap | $642.54M | -70.5% |
| Market Cap / Employee | $4.34M | 0.0% |
| Employees | 148 | 0.0% |
| Net Income | -$7.28M | 86.3% |
| EBITDA | -$14.99M | 74.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $693.47M | 30.7% |
| Accounts Receivable | $3.49M | 800.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $15.11M | -13.3% |
| Short Term Debt | $2.32M | 24.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 9.75% | 49.9% |
| Return On Invested Capital | -30.72% | 32.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $3.12M | 110.1% |
| Operating Free Cash Flow | $3.25M | 110.7% |
| Metric | Q2 2025 | Q3 2025 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 42.61 | 10.25 | - | ||
| Price to Book | 1.17 | 0.72 | 0.74 | 0.91 | -81.78% |
| Price to Sales | 179.87 | 1.95 | 2.33 | 2.60 | -99.92% |
| Price to Tangible Book Value | 1.17 | 0.72 | 0.74 | 0.91 | -81.78% |
| Price to Free Cash Flow TTM | 9.65 | 10.21 | 7.38 | - | |
| Enterprise Value to EBITDA | -1.84 | -1.86 | 3.30 | 2.23 | -107.77% |
| Free Cash Flow Yield | 10.4% | 9.8% | 13.6% | - | |
| Return on Equity | -41.5% | 0.7% | 3.3% | 10.4% | -123.79% |
| Total Debt | $18.86M | $18.41M | $17.95M | $17.43M | -9.63% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
